263 GSK Annual Report 2016 Strategic report Governance and remuneration Financial statements Investor information Shareholder information Share capital and control Details of our issued share capital and the number of shares Share buy-back programme held in Treasury as at 31 December 2016 can be found in The Board has been authorised to issue and allot Ordinary Shares Note 33 to the financial statements, Share capital and share under Article 9 of the companys Articles of Association.
under Article 9 and the authority for the company to make purchases of its own shares are subject to shareholder authorities which are Our Ordinary Shares are listed on the London Stock Exchange sought on an annual basis at our Annual General Meeting AGM.
and are also quoted on the New York Stock Exchange NYSE Any shares purchased by the company may be cancelled or held as in the form of American Depositary Shares ADS.
Each ADS Treasury shares or used for satisfying share options and grants under represents two Ordinary Shares.
For details of listed debt and Group employee share plans.
where it is listed refer to Note 31 to the financial statements, Net debt.
Our programme covers purchases of shares for cancellation or to be held as Treasury shares, in accordance with the authority Holders of Ordinary Shares and ADS are entitled to receive renewed by shareholders at the AGM in May 2016, when the dividends when declared, the companys Annual Report, to attend company was authorised to purchase a maximum of just over and speak at general meetings of the company, to appoint proxies 487 million shares.
Details of shares purchased, those cancelled, and to exercise voting rights.
those held as Treasury shares and those subsequently transferred There are no restrictions on the transfer, or limitations on the holding, from Treasury to satisfy awards under the Groups share plans are of Ordinary Shares and ADS and no requirements to obtain approval disclosed in Note 33 to the financial statements, Share capital and prior to any transfers.
No Ordinary Shares or ADS carry any special share premium account.
rights with regard to control of the company and there are no In determining specic share repurchase levels, the company restrictions on voting rights.
Major shareholders have the same voting considers the development of free cash ow during the year.
Given rights per share as all other shareholders.
There are no known the impact of the sustained strength of Sterling on free cash ow, arrangements under which financial rights are held by a person other the company suspended its share repurchase programme during than the holder of the shares and no known agreements on 2014 and no shares were purchased during the financial years restrictions on share transfers or on voting rights.
Shares acquired through our share schemes and plans rank equally The company confirms that it does not currently intend to make with the other shares in issue and have no special rights.
The any further market purchases in 2017.
The company will review trustees of our Employee Share Ownership Plan trusts have waived the potential for future share buy-backs during 2018 in line with their rights to dividends on shares held by those trusts.
its usual annual cycle and subject to return and ratings criteria.
Exchange controls and other limitations affecting security holders Market capitalisation Other than certain economic sanctions, which may be in force The market capitalisation, based on shares in issue excluding from time to time, there are currently no applicable laws, decrees Treasury shares, of GSK at 31 December 2016 was 76.69 billion.
or regulations in force in the UK restricting the import or export of At that date, GSK was the fifth largest company by market capital or affecting the remittance of dividends or other payments to capitalisation in the FTSE index.
holders of the companys shares who are non-residents of the UK.
Similarly, other than certain economic sanctions which may be in Share price 2016 2015 2014 force from time to time, there are no limitations relating only to non-residents of the UK under English law or the companys Articles At 1 January 13.73 13.76 16.12 of Association on the right to be a holder of, and to vote in respect of, At 31 December 15.62 13.73 13.76 the companys shares.
Decrease increase 13.8% 0.2 % 14.6 % Interests in voting rights High during the year 17.22 16.42 16.91 Other than as stated below, as far as we are aware, there are no Low during the year 13.44 12.38 13.24 persons with significant direct or indirect holdings in the company.
Information provided to the company pursuant to the Financial The table above sets out the middle market closing prices.
The Conduct Authoritys FCA Disclosure and Transparency Rules companys share price increased by 13.8% in 2016.
This compares DTRs is published on a Regulatory Information Service and on with an increase in the FTSE 100 index of 14.4% during the year.
The share price on 3 March 2017 was 16.88.
At 3 March 2017, the company had received notications in accordance with the FCAs DTRs of the following notiable interests UK US$ in the voting rights in the companys issued share capital: 75 18 Percentage of 17 70 No.
of issued 16 65 shares capital % 15 60 BlackRock, Inc. 327,305,939 6.66 14 55 Percentage of Ordinary Shares in issue, excluding Treasury shares.
13 50 We have not acquired or disposed of any interests in our own 12 45 shares during the period under review, with the exception of those 11 40 transferred from Treasury to satisfy awards under the Groups 35 10 share plans.
09 30 31 12 13 31 12 14 31 12 15 31 12 16 UK share price UK US ADS price US$ 264 GSK Annual Report 2016 Shareholder information continued Share capital and control continued Nature of trading market The following tables set out, for the periods indicated, the high and low middle market closing quotations in pence for the shares on the London Stock Exchange, and the high and low closing prices in US dollars for the ADS on the NYSE.
Ordinary Shares representing the companys ADR programme, which is managed by the Depositary, are registered in the name of BNY Nominees Limited.
At 3 March 2017, BNY Nominees Limited held 848,389,001 Ordinary Shares representing 17.25% of the issued share capital excluding Treasury shares at that date.
At 3 March 2017, the number of holders of Ordinary Shares in the US was 1,022 with holdings of 1,091,064 Ordinary Shares, and the number of registered holders of ADS was 22,622 with holdings of 424,194,500 ADS.
Certain of these Ordinary Shares and ADS were held by brokers or other nominees.
As a result, the number of holders of record or registered holders in the US is not representative of the number of beneficial holders or of the residence of beneficial holders.
